Amgen

Amgen takes next step with its China ambitions, out-licensing drugs to Fosun Pharma
Amgen takes next step with its China ambitions, out-licensing drugs to Fosun Pharma
Endpoints
Amgen
China
Fosun Pharmaceutical
Flag link:
As biosimilars gain steam, Amgen exec lays out its Humira copycat plans
As biosimilars gain steam, Amgen exec lays out its Humira copycat plans
Fierce Pharma
Amgen
Humira
biosimilars
Flag link:
Cytokinetics aims to become the Vertex of cardiovascular disease
Cytokinetics aims to become the Vertex of cardiovascular disease
EP Vantage
Cytokinetics
Amgen
heart failure
Omecamtiv Mecarbil
cardiovascular disease
Flag link:
ASCO 2022 – the spirit of Rova-T struggles to live on
ASCO 2022 – the spirit of Rova-T struggles to live on
EP Vantage
ASCO 2022
Rova-T
AbbVie
Harpoon Therapeutics
Amgen
Boehringer Ingelheim
Flag link:
ASCO: It's all tied up? Mirati's KRAS data are 'identical' to Amgen's, researcher says
ASCO: It's all tied up? Mirati's KRAS data are 'identical' to Amgen's, researcher says
Fierce Biotech
ASCO 2022
Mirati Therapeutics
Amgen
Lumakras
adagrasib
lung cancer
Flag link:
Regeneron's cholesterol drug war heats up with lawsuit over Amgen's 'illegal' bundling scheme
Regeneron's cholesterol drug war heats up with lawsuit over Amgen's 'illegal' bundling scheme
Fierce Pharma
Regeneron
Amgen
FDA
antitrust
legal
Repatha
Praluent
Flag link:
Amgen eyes swift move to ph3 for cardiovascular drug olpasiran
Amgen eyes swift move to ph3 for cardiovascular drug olpasiran
Pharmaforum
Amgen
olpasiran
Novartis
clinical trials
cardiovascular disease
Flag link:
Amneal scores third biosimilar approval in three months
Amneal scores third biosimilar approval in three months
Biopharma Reporter
Amneal
FDA
biosimilars
pegfilgrastim
Fylnetra
Amgen
Neulasta
Flag link:
Mirati matches Amgen with updated data for KRAS-blocking cancer drug
Mirati matches Amgen with updated data for KRAS-blocking cancer drug
BioPharma Dive
Mirati Therapeutics
Amgen
KRAS
adagrasib
Lumakras
clinical trials
Flag link:
Bristol's Abecma, Amgen's Lumakras headline record-setting oncology launch class as costs continue to balloon: IQVIA
Bristol's Abecma, Amgen's Lumakras headline record-setting oncology launch class as costs continue to balloon: IQVIA
Fierce Pharma
oncology
cancer
IQVIA
Bristol Myers Squibb
Abecma
Amgen
Lumakras
Flag link:
Could This Biosimilar Drug Candidate Create a Blockbuster for Amgen?
Could This Biosimilar Drug Candidate Create a Blockbuster for Amgen?
Motley Fool
Amgen
biosimilars
Stelara
JNJ
Flag link:
Amgen celebrates 25 years of deCODE Genetics as partnership evolves from discovery to development
Amgen celebrates 25 years of deCODE Genetics as partnership evolves from discovery to development
Fierce Biotech
Amgen
M&A
deCODE Genetics
drug discovery
drug development
Flag link:
Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data
Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data
Fierce Biotech
Bristol Myers Squibb
deucravacitinib
clinical trials
psoriasis
Amgen
Otezla
Flag link:
The 12 Top Biotech Companies Hiring Now
The 12 Top Biotech Companies Hiring Now
BioSpace
biotech
life sciences
hirings
Regeneron
Pfizer
Amgen
AbbVie
Moderna Therapeutics
CSL Behring
Waters Corporation
Daiichi Sankyo
Gilead Sciences
Grail
Emergent BioSolutions
resilience
Flag link:
Amgen spinout Kezar hits PhII hurdle, all eyes on June readout for drug’s other study
Amgen spinout Kezar hits PhII hurdle, all eyes on June readout for drug’s other study
Endpoints
Amgen
Kezar Life Sciences
zetomipzomib
autoimmune disease
dermatomyositis
polymyositis
Flag link:
Amgen Battles IRS Over Billions in "Wholly Unwarranted" Tax Penalties
Amgen Battles IRS Over Billions in "Wholly Unwarranted" Tax Penalties
BioSpace
Amgen
earnings
taxes
IRS
Flag link:
A bad day for Molecular Partners
A bad day for Molecular Partners
EP Vantage
Molecular Partners
MP0310
Amgen
Novartis
ensovibep
Flag link:
Thought CETP inhibition was dead? Think again
Thought CETP inhibition was dead? Think again
EP Vantage
New Amsterdam
Amgen
CETP inhibitors
obicetrapib
Flag link:
Amgen parts ways with part of Ventura County headquarters campus: report
Amgen parts ways with part of Ventura County headquarters campus: report
Fierce Pharma
Amgen
California
headquarters
Flag link:
Novartis Highlights Early Data from Potential Lumakras Competitor at AACR
Novartis Highlights Early Data from Potential Lumakras Competitor at AACR
BioSpace
Novartis
AACR
JDQ443
clinical trials
Amgen
Lumakras
Flag link:

Pages